Portfolio Companies
Skinject Inc., a wholly owned subsidiary of Medicus Pharma Ltd. (NASDAQ:MDCX), is a development stage biotechnology life sciences company focused on developing and commercializing, a novel, localized. Immuno-oncology precision product, focused on non-melanoma skin diseases, especially basal cell carcinoma, and Gorlin Syndrome, a rare autosomal dominant disease also called Nevoid Basal Cell Carcinoma Syndrome. Watch our Skinject explainer video
>5 million
Basal Cell Carcinoma cases annually in the U.S. according to PubMed
$2 Billion
Annual Basal Cell Carcinoma Market Opportunity
Skinject US Patents granted for method of use through 2035
Skinject phase 2 clinical trial enrollment has begun